Epigenetic drivers of localised prostate cancers reveal neuronal and microenvironmental reprogramming and inform liquid biopsy biomarkers
Milne-Clark T*, Lee Yu H*, Nazlamova L, Martin H, Amin AD, Cheung M, Faulkner L, Batra R, Robb T, Youssef G, Warren A, Leung W-K, CRUK-ICGC Prostate Cancer Group, Gnanapragasam V, Pacey S, Wedge D, Eeles R, Cooper C, Brewer DS, Han N, Lynch AG, Massie C, Dev H. *Equal Contribution.
SSRN (pre-print) online: 26 January 2026
Publications
In vivo screen in benign prostate epithelium identifies loss of alpha-catenin as a driver of metastasis and androgen insensitivity
Comer M*, Hart A*, Lee Yu H, Nazlamova L, Milne-Clark T, Thomas J, Mahalingam V, Dobson L, Robb T, Palma-Reis Goldie F, Hautaviita K, Elwakeel A, Field S, Patikas N, Barber H, Cheung M, Machesky L, Fernandez-Vega I, Metzakopian E, Bradley A, Dev H^, de la Rosa J^. *^Equal contributions
SSRN (pre-print) 2025 dx.doi.org/10.2139/ssrn.5771963
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair
Illuzzi G, Galbiati A, Staniszewska AD, Hanson R, Michaloglou C, Cooke SL, Uznańska K, Białecka M, Solarczyk K, Dev HS, Massie CE, Albertella MR, Leo E, Forment JV, O'Connor MJ.
Nucleic Acids Research Cancer 2025 Oct 7;7(4)
Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects
Palma Dos Reis AF, Faulkner LG, Lai IW, Dev H, Pacey S.
Clin Oncol (R Coll Radiol). 2025 Aug;44:103804.
Cambridge neoadjuvant cancer of the prostate (CAN-CAP03): a window study into the effects of olaparib ± degarelix in primary prostate cancer
Dev H, Linch M, Narahari K, Milne-Clark T, Cheung M, Warren A, Malaviya A, Gnanapragasam V, Hernandez T, Bullock N, Machin A, Dayimu A, Robb T, Cromwell E, Freeman A, Harrington EA, Camacho N, Glont S, Squatrito M, Rotem A, Moore L, Hanson R, Dodd M, Anand S, Kynaston H, Shaw G, Shah N, Pacey S.
Clinical Cancer Research 2025 Jun 13;31(12):2347-2357.
Prostate cancer detection through unbiased capture of methylated cell-free DNA
Lleshi E, Milne-Clark T, Lee Yu H, Martin HW, Hanson R, Lach R, Rossi SH, Riediger AL, Görtz M, Sültmann H, Flewitt A, Lynch AG, Gnanapragasam VJ, Massie CE, Dev HS.
iScience 2024 Jun 20;27(7):110330.
Ultrasensitive detection of circulating tumour DNA enriches for patients with a greater risk of recurrence of clinically localised prostate cancer
Pope B, Park G, Lau E, Belic J, Lach R, George A, McCoy P, Nguyen A, Grima C, Campbell B, Jung CH, Ditter EJ, Zhao H; Pan Prostate Cancer Group (PPCG); Wedge DC, Brewer DS, Lynch AG, Dev H, Gnanpragasam VJ, Rosenfeld N, Hovens CM, Corcoran NM, Massie CE.
European Urology 2024 Apr;85(4):407-410.
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, Herzog M, Lam J, Shea A, Demir M, Wu Q, Yang F, Fu B, Lai Z, Balmus G, Belotserkovskaya R, Serra V, O'Connor MJ, Bruna A, Beli P, Pellegrini L, Caldas C, Deriano L, Jacobs JJL, Galanty Y, Jackson SP.
Nature Cell Biology 2018 Aug;20(8):954-965.
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O'Neill C, Zecchini VR, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal D, Helleday T.
Nature Communications 2017 Aug 29;8(1):374.